Evidence map›Paper›PMID 35269629›Full record

ReviewInternational journal of molecular sciences2022

Alzheimer's Disease Seen through the Eye: Ocular Alterations and Neurodegeneration.

Daniel Romaus-Sanjurjo, Uxía Regueiro, Maite López-López, Laura Vázquez-Vázquez, Alberto Ouro, Isabel Lema, Tomás Sobrino

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Visual field defects in dementia: A scoping review.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2025
    Pooled it
  2. Pooled it
  3. Review
  4. Tear fluid participates in systemic immunity.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Potential Retinal Biomarkers in Alzheimer's Disease.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Daniel Romaus-SanjurjoNeuroAging Group (NEURAL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.ORCID 0000-0001-7715-1956
Uxía RegueiroCorneal Neurodegeneration Group (RENOIR), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.ORCID 0000-0001-9633-2701
Maite López-LópezCorneal Neurodegeneration Group (RENOIR), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.
Laura Vázquez-VázquezNeuroAging Group (NEURAL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.
Alberto OuroNeuroAging Group (NEURAL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.ORCID 0000-0003-4359-1704
Isabel LemaCorneal Neurodegeneration Group (RENOIR), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.
Tomás SobrinoNeuroAging Group (NEURAL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), 15706 Santiago de Compostela, Spain.ORCID 0000-0002-9760-8690
Instituto de Investigación Sanitaria de Santiago · ESUniversidade de Santiago de Compostela · ES

Funding

European Commission 686009Instituto de Salud Carlos III CPII17/00027, CD21/00166INTERREG Atlantic Area EAPA_791/2018_ NEUROATLANTIC projectINTER-REG V A España Portugal - POCTEP 0624_2IQBIONEURO_6_EMinistry of Economy, Industry and Competitiveness PI18/00159Ministry of Science RTI2018-102165-B-I00, RTC2019-007373-1Spanish Research Network on Cerebrovascular Diseases - INVICTUS PLUS RD16/0019/0001Xunta de Galicia IN606B-2021/001Xunta de Galicia IN606B-2021/010Xunta de Galicia IN607A2018/3Xunta de Galicia IN607D 2020/09
6 · The paper itself

Abstract

Alzheimer's Disease (AD) is one of the main neurodegenerative diseases worldwide. Unfortunately, AD shares many similarities with other dementias at early stages, which impedes an accurate

Indexed as

Alzheimer DiseaseEye DiseasesAmyloid beta-PeptidesBiomarkersEarly DiagnosisHumansRetinatau ProteinsAmyloid beta-PeptidesBiomarkerstau ProteinsAlzheimer’s Diseaseamyloid burdenanterior segmentaqueous humorbiomarkerscorneaposterior segmentretinatautear fluid

Identifiers

PMID35269629
PMCPMC8910735
OpenAlexW4213453634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.